Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data

MOTIVATION Targeted kinase inhibitors have dramatically improved cancer treatment, but kinase dependency for an individual patient or cancer cell can be challenging to predict. Kinase dependency does not always correspond with gene expression and mutation status. High-throughput drug screens are powerful tools for determining kinase dependency, but drug polypharmacology can make results difficult to interpret. RESULTS We developed Kinase Addiction Ranker (KAR), an algorithm that integrates high-throughput drug screening data, comprehensive kinase inhibition data and gene expression profiles to identify kinase dependency in cancer cells. We applied KAR to predict kinase dependency of 21 lung cancer cell lines and 151 leukemia patient samples using published datasets. We experimentally validated KAR predictions of FGFR and MTOR dependence in lung cancer cell line H1581, showing synergistic reduction in proliferation after combining ponatinib and AZD8055. AVAILABILITY AND IMPLEMENTATION KAR can be downloaded as a Python function or a MATLAB script along with example inputs and outputs at: http://tanlab.ucdenver.edu/KAR/. CONTACT aikchoon.tan@ucdenver.edu. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.

[1]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[2]  F. Hirsch,et al.  The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Jaewoo Kang,et al.  Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy , 2014, Bioinform..

[4]  K. Flaherty,et al.  TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma , 2013, Science Translational Medicine.

[5]  Andrew P. Hodges,et al.  Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression , 2013, BMC Systems Biology.

[6]  F. Hirsch,et al.  FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies , 2014, Clinical Cancer Research.

[7]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[8]  Jihye Kim,et al.  DSigDB: drug signatures database for gene set analysis , 2015, Bioinform..

[9]  Jae Cheol Lee,et al.  AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells. , 2015, Anticancer research.

[10]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[11]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[12]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[13]  David Hsieh,et al.  Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells , 2013, Journal of cellular and molecular medicine.

[14]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[15]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[16]  René Bernards,et al.  Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. , 2014, Trends in biochemical sciences.

[17]  N. Rosen,et al.  mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer , 2013, Science Translational Medicine.

[18]  B. Druker,et al.  RNAi screen for rapid therapeutic target identification in leukemia patients , 2009, Proceedings of the National Academy of Sciences.

[19]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[20]  Armand Bankhead,et al.  Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. , 2013, Cancer research.

[21]  John Kuriyan,et al.  Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.

[22]  B. Manning,et al.  mTORC1 Status Dictates Tumor Response to Targeted Therapeutics , 2013, Science Signaling.

[23]  P. Zarrinkar,et al.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.

[24]  M. Rask-Andersen,et al.  The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. , 2014, Annual review of pharmacology and toxicology.

[25]  P. Qiu,et al.  Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells , 2013, Oncotarget.

[26]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[27]  Ranadip Pal,et al.  A new approach for prediction of tumor sensitivity to targeted drugs based on functional data , 2013, BMC Bioinformatics.

[28]  Karen A. Ryall,et al.  Systems biology approaches for advancing the discovery of effective drug combinations , 2015, Journal of Cheminformatics.

[29]  P. Petronini,et al.  Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. , 2014, Biochemical pharmacology.

[30]  L. Peshkin,et al.  Exploiting polypharmacology for drug target deconvolution , 2014, Proceedings of the National Academy of Sciences.

[31]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[32]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[33]  M. Glickman,et al.  Converting Cancer Therapies into Cures: Lessons from Infectious Diseases , 2012, Cell.

[34]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[35]  Katherine R. Singleton,et al.  Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. , 2015, Cancer research.

[36]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[37]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.